Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.

We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.

If you need assistance finding or assessing business development and/or partnership opportunities, contact us at

Current Projects

Oncology Biosimilars  
Posted on Aug 13, 2014

Our US-based client has developed production cell lines ready for the scale up and manufacturing of biosimilar versions of three leading monoclonal antibodies:
  • Trastuzumab

Wnt Activators for Osteoporosis: First In Class Opportunity  
Posted on Mar 02, 2012



There are two general mechanisms of action for treating osteoporosis: Anti-Resorption Agents inhibit the normal resorption of bone, thereby slowing bone loss. But, this approach does not trigger de novo bone for
  Read More»

Urotensin II Receptor Antagonists Available for Licensing  
Posted on Sep 02, 2014

  The Urotensin II receptor is highly expressed in blood vessels, heart, lung and brain. Up-regulation of the Urotensin II receptor in patients with congestive heart failure and pulmonary hypertension is well-documented. Our client has discovered two potent orally bioavailable antagonists of the Urotensin II receptor. Both of these are more effective than the
  Read More»

Our Latest Article

Lacerta Bio at BIO Europe 2014 
Posted on Sep 02, 2014


Lacerta Bio is pleased to return to Europe for the 20th Anniversary of the BIO-Europe conference.

We will be there from Sunday evening through Wednesday afternoon.

Look for us in PartneringOne, or contact us at to schedule a meeting with us.

You can also follow the action on Twitter via the #BEU14 hashtag.

Latest Posts

Wanted: Guest Bloggers 
Posted on Aug 14, 2014

We’re actively seeking guest bloggers for! The ideal guest blogger:   – Is currently involved in business development and licensing  - Currently works for a pharma, biotech, VC, PE, or consultancy  - Is able to write 500+ word articles related to business development and licensing The key is to have high quality, original, insightful Read More »

Afrezza Partnered…Now What? 
Posted on Aug 11, 2014

    This morning we learned that Sanofi is the winner in the “Where on Earth is the Partner for Afrezza?” sweepstakes. We’ll defer to the many news outlets for the details. But one interesting take on the deal is from A few good points were raised: Sanofi advanced $175 MM to MannKind as Read More »

Daiichi Sankyo Pay Millions for…Acetaminophen? 
Posted on Aug 07, 2014

Yes, and it might be worth it. Yesterday, Daiichi Sankyo announced an incredible $650 million deal with Florida-based Charleston Laboratories for the development and commercialization of a family of fixed dose combination products. The lead candidate, CL-108, is a fixed dose combination of promethazine, hydrocodone, and acetaminophen. The deal was signed on the back of Read More »